文献速递前列腺癌

PSA游离比在PSA低于4 ng/mL男性中预测临床显著前列腺癌的价值

Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL.
PubMed 文献 · BJU Int · 2024-11-28

基于前列腺癌预防试验数据,纳入406例PSA≤4 ng/mL且一年内接受活检的男性,分析PSA游离比与临床显著前列腺癌(csPCa)的关系。结果显示FTR≤0.15者csPCa比例为46%,FTR≥0.20者为22%;在PSA和年龄基础上加入FTR可提高预测准确性和净获益。

要点

  • 在PSA≤4 ng/mL且需活检的男性中,低PSA游离比与更高的临床显著前列腺癌风险相关。
  • FTR≤0.15者csPCa比例为46%,而FTR≥0.20者为22%。
  • FTR可作为附加的、易得且廉价的检测指标,用于改善csPCa预测并辅助患者咨询。

核心结论

  • 在PSA 1.5–4 ng/mL且其他方面具备活检指征的中年男性中,低PSA游离比与更高的临床显著前列腺癌发生率相关。
  • PSA游离比应作为附加的、易得且廉价的检测指标,用于改善临床显著前列腺癌的预测并辅助患者咨询。

研究设计与样本

  • 研究数据来自前列腺癌预防试验。
  • 纳入PSA≤4 ng/mL且在该PSA测量后一年内接受活检的患者,共分析406例。

主要发现

  • 406例中139例(34%)患有临床显著前列腺癌,204例(50%)患有任何级别前列腺癌。
  • PSA游离比≤0.15者中46%患有临床显著前列腺癌,而PSA游离比≥0.20者中该比例为22%。
  • 在回归模型中,60岁且PSA为3 ng/mL者,若PSA游离比为0.05则临床显著前列腺癌预测概率为61%,若PSA游离比为0.30则降至18%。
  • 观察到PSA游离比升高与临床显著前列腺癌概率之间存在明确的负相关关系。

关键数值与推荐

  • 在PSA和年龄基础上加入PSA游离比的模型,按决策曲线分析提供更大的净获益,并可能具有更优的判别能力和校准度(以更高的预测准确性指数衡量)。

临床怎么用

  • 对于PSA 1.5–4 ng/mL且其他方面具备活检指征的中年男性,可考虑使用PSA游离比作为附加检测来改善临床显著前列腺癌的预测并辅助患者咨询(作者建议)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the relationship between the prostate-specific antigen (PSA) free-to-total ratio (FTR) and International Society of Urological Pathology Grade Group ≥2, clinically significant prostate cancer (csPCa) in men with a low PSA level (≤4 ng/mL). Patients and Methods Data were obtained from the Prostate Cancer Prevention Trial. Patients with a PSA level of ≤4 ng/mL and who received a biopsy within a year of this PSA measurement were included. Associations between FTR and csPCa were investigated with logistic regression, adjusting for age and PSA, a re-scaled Brier score (index of predictive accuracy), and decision curve analysis. RESULTS: A total of 406 patients were analysed with 139 (34%) having csPCa and 204 (50%) having any grade PCa. For those with an FTR ≤0.15, 46% had csPCa, vs 22% for those with a ratio ≥0.20. In a regression model, the predicted probability of csPCa for a 60-year-old with a PSA of 3 ng/mL was 61% if the FTR was 0.05, falling to 18% if the FTR was 0.30. A clear negative relationship between increasing FTR and probability of csPCa was observed. A model containing FTR additional to PSA and age provides greater net benefit as per decision curve analysis and likely superior discrimination and calibration measured by a higher index of predictive accuracy. CONCLUSIONS: In middle-aged men with a PSA level between 1.5 and 4 ng/mL but otherwise indicated for biopsy, a low FTR is associated with higher rates of csPCa. It should be utilised as an additional, readily available and inexpensive test to improve prediction of csPCa and aid in patient counselling.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Sii S, Papa N, Yiu TW, et al. Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL. BJU Int. 2024. PMID: 39607059. doi:10.1111/bju.16597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。